{
    "answer": "In the EU, Kisqali is approved for the treatment of women with HR+/HER2- advanced or MBC in combination with either an AI or fulvestrant.",
    "ground_truth": "Treating hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (adjuvant)",
    "rewards": [
        0,
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 3,
    "search count": 2,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        813,
        2005,
        3483
    ]
}